COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma
Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identi...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical oncology 2022-12, Vol.40 (36), p.4178-4188 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4188 |
|---|---|
| container_issue | 36 |
| container_start_page | 4178 |
| container_title | Journal of clinical oncology |
| container_volume | 40 |
| creator | Dummer, Reinhard Flaherty, Keith T Robert, Caroline Arance, Ana de Groot, Jan Willem B Garbe, Claus Gogas, Helen J Gutzmer, Ralf Krajsová, Ivana Liszkay, Gabriella Loquai, Carmen Mandalà, Mario Schadendorf, Dirk Yamazaki, Naoya di Pietro, Alessandra Cantey-Kiser, Jean Edwards, Michelle Ascierto, Paolo A |
| description | Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced
V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).
Patients with locally advanced unresectable or metastatic
V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned.
Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.
In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with
V600-mutant melanoma. |
| doi_str_mv | 10.1200/JCO.21.02659 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9916040</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2693779548</sourcerecordid><originalsourceid>FETCH-LOGICAL-c346t-27b9b02e8a214030a1d3df589c16dd65c6b2aceb6e356b45f5efe7cfaedc86ca3</originalsourceid><addsrcrecordid>eNpVkU2P0zAQhi0EYkvhxhn5yKEp_qidhANSW-1CUatWy7bAyZo4E2qUxMVOkOBH8RvJsh9iTyO9887MO3oIecnZlAvG3nxcbqeCT5nQKn9ERlyJNElTpR6TEUulSHgmv5yRZzF-Z4zPMqmekjOpMi2ylI_In-V2vd8s9p-oSr4iBLo_ldDhWzqnl9CWvnG_sZzQ7QnbZA0F1hO6O0JEulqt6FVwUFNf0fPW-gAVtq6gu7qPdOFa12DnroUDhjhIB2z6O48PD0ZcS3fQOWy7SD-77kgXl_MLetCMJZu-g7ajG6yh9Q08J08qqCO-uK1jsr84v1p-SNbb96vlfJ1YOdNdItIiL5jADASfMcmAl7KsVJZbrstSK6sLARYLjVLpYqYqhRWmtgIsbaYtyDF5d7P31BfNIA7RAtTmFFwD4Zfx4MzDTuuO5pv_afKcazacHJPXtwuC_9Fj7EzjosV6eAN9H43QuUzTXA1AxmRyY7XBxxiwuj_DmblGbAbERnDzD_Fgf_V_tHvzHVP5F714oxM</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2693779548</pqid></control><display><type>article</type><title>COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma</title><source>MEDLINE</source><source>American Society of Clinical Oncology Online Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><creator>Dummer, Reinhard ; Flaherty, Keith T ; Robert, Caroline ; Arance, Ana ; de Groot, Jan Willem B ; Garbe, Claus ; Gogas, Helen J ; Gutzmer, Ralf ; Krajsová, Ivana ; Liszkay, Gabriella ; Loquai, Carmen ; Mandalà, Mario ; Schadendorf, Dirk ; Yamazaki, Naoya ; di Pietro, Alessandra ; Cantey-Kiser, Jean ; Edwards, Michelle ; Ascierto, Paolo A</creator><creatorcontrib>Dummer, Reinhard ; Flaherty, Keith T ; Robert, Caroline ; Arance, Ana ; de Groot, Jan Willem B ; Garbe, Claus ; Gogas, Helen J ; Gutzmer, Ralf ; Krajsová, Ivana ; Liszkay, Gabriella ; Loquai, Carmen ; Mandalà, Mario ; Schadendorf, Dirk ; Yamazaki, Naoya ; di Pietro, Alessandra ; Cantey-Kiser, Jean ; Edwards, Michelle ; Ascierto, Paolo A</creatorcontrib><description>Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced
V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).
Patients with locally advanced unresectable or metastatic
V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned.
Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.
In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with
V600-mutant melanoma.</description><identifier>ISSN: 0732-183X</identifier><identifier>EISSN: 1527-7755</identifier><identifier>DOI: 10.1200/JCO.21.02659</identifier><identifier>PMID: 35862871</identifier><language>eng</language><publisher>United States: Wolters Kluwer Health</publisher><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects ; Humans ; Lactate Dehydrogenases ; Melanoma - drug therapy ; Melanoma - genetics ; Mutation ; ORIGINAL REPORTS ; Proto-Oncogene Proteins B-raf - genetics ; Skin Neoplasms - drug therapy ; Skin Neoplasms - genetics ; Vemurafenib - therapeutic use</subject><ispartof>Journal of clinical oncology, 2022-12, Vol.40 (36), p.4178-4188</ispartof><rights>2022 by American Society of Clinical Oncology 2022 American Society of Clinical Oncology</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c346t-27b9b02e8a214030a1d3df589c16dd65c6b2aceb6e356b45f5efe7cfaedc86ca3</citedby><cites>FETCH-LOGICAL-c346t-27b9b02e8a214030a1d3df589c16dd65c6b2aceb6e356b45f5efe7cfaedc86ca3</cites><orcidid>0000-0002-2279-6906 ; 0000-0002-9493-0238 ; 0000-0002-8322-475X ; 0000-0002-0451-2885 ; 0000-0001-8846-8959 ; 0000-0002-9638-0428 ; 0000-0003-2896-1957 ; 0000-0001-8530-780X ; 0000-0003-3524-7858 ; 0000-0001-7921-2820 ; 0000-0002-3402-0478</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3716,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/35862871$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Flaherty, Keith T</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Arance, Ana</creatorcontrib><creatorcontrib>de Groot, Jan Willem B</creatorcontrib><creatorcontrib>Garbe, Claus</creatorcontrib><creatorcontrib>Gogas, Helen J</creatorcontrib><creatorcontrib>Gutzmer, Ralf</creatorcontrib><creatorcontrib>Krajsová, Ivana</creatorcontrib><creatorcontrib>Liszkay, Gabriella</creatorcontrib><creatorcontrib>Loquai, Carmen</creatorcontrib><creatorcontrib>Mandalà, Mario</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Yamazaki, Naoya</creatorcontrib><creatorcontrib>di Pietro, Alessandra</creatorcontrib><creatorcontrib>Cantey-Kiser, Jean</creatorcontrib><creatorcontrib>Edwards, Michelle</creatorcontrib><creatorcontrib>Ascierto, Paolo A</creatorcontrib><title>COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma</title><title>Journal of clinical oncology</title><addtitle>J Clin Oncol</addtitle><description>Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced
V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).
Patients with locally advanced unresectable or metastatic
V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned.
Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.
In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with
V600-mutant melanoma.</description><subject>Antineoplastic Combined Chemotherapy Protocols - adverse effects</subject><subject>Humans</subject><subject>Lactate Dehydrogenases</subject><subject>Melanoma - drug therapy</subject><subject>Melanoma - genetics</subject><subject>Mutation</subject><subject>ORIGINAL REPORTS</subject><subject>Proto-Oncogene Proteins B-raf - genetics</subject><subject>Skin Neoplasms - drug therapy</subject><subject>Skin Neoplasms - genetics</subject><subject>Vemurafenib - therapeutic use</subject><issn>0732-183X</issn><issn>1527-7755</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkU2P0zAQhi0EYkvhxhn5yKEp_qidhANSW-1CUatWy7bAyZo4E2qUxMVOkOBH8RvJsh9iTyO9887MO3oIecnZlAvG3nxcbqeCT5nQKn9ERlyJNElTpR6TEUulSHgmv5yRZzF-Z4zPMqmekjOpMi2ylI_In-V2vd8s9p-oSr4iBLo_ldDhWzqnl9CWvnG_sZzQ7QnbZA0F1hO6O0JEulqt6FVwUFNf0fPW-gAVtq6gu7qPdOFa12DnroUDhjhIB2z6O48PD0ZcS3fQOWy7SD-77kgXl_MLetCMJZu-g7ajG6yh9Q08J08qqCO-uK1jsr84v1p-SNbb96vlfJ1YOdNdItIiL5jADASfMcmAl7KsVJZbrstSK6sLARYLjVLpYqYqhRWmtgIsbaYtyDF5d7P31BfNIA7RAtTmFFwD4Zfx4MzDTuuO5pv_afKcazacHJPXtwuC_9Fj7EzjosV6eAN9H43QuUzTXA1AxmRyY7XBxxiwuj_DmblGbAbERnDzD_Fgf_V_tHvzHVP5F714oxM</recordid><startdate>20221220</startdate><enddate>20221220</enddate><creator>Dummer, Reinhard</creator><creator>Flaherty, Keith T</creator><creator>Robert, Caroline</creator><creator>Arance, Ana</creator><creator>de Groot, Jan Willem B</creator><creator>Garbe, Claus</creator><creator>Gogas, Helen J</creator><creator>Gutzmer, Ralf</creator><creator>Krajsová, Ivana</creator><creator>Liszkay, Gabriella</creator><creator>Loquai, Carmen</creator><creator>Mandalà, Mario</creator><creator>Schadendorf, Dirk</creator><creator>Yamazaki, Naoya</creator><creator>di Pietro, Alessandra</creator><creator>Cantey-Kiser, Jean</creator><creator>Edwards, Michelle</creator><creator>Ascierto, Paolo A</creator><general>Wolters Kluwer Health</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2279-6906</orcidid><orcidid>https://orcid.org/0000-0002-9493-0238</orcidid><orcidid>https://orcid.org/0000-0002-8322-475X</orcidid><orcidid>https://orcid.org/0000-0002-0451-2885</orcidid><orcidid>https://orcid.org/0000-0001-8846-8959</orcidid><orcidid>https://orcid.org/0000-0002-9638-0428</orcidid><orcidid>https://orcid.org/0000-0003-2896-1957</orcidid><orcidid>https://orcid.org/0000-0001-8530-780X</orcidid><orcidid>https://orcid.org/0000-0003-3524-7858</orcidid><orcidid>https://orcid.org/0000-0001-7921-2820</orcidid><orcidid>https://orcid.org/0000-0002-3402-0478</orcidid></search><sort><creationdate>20221220</creationdate><title>COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma</title><author>Dummer, Reinhard ; Flaherty, Keith T ; Robert, Caroline ; Arance, Ana ; de Groot, Jan Willem B ; Garbe, Claus ; Gogas, Helen J ; Gutzmer, Ralf ; Krajsová, Ivana ; Liszkay, Gabriella ; Loquai, Carmen ; Mandalà, Mario ; Schadendorf, Dirk ; Yamazaki, Naoya ; di Pietro, Alessandra ; Cantey-Kiser, Jean ; Edwards, Michelle ; Ascierto, Paolo A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c346t-27b9b02e8a214030a1d3df589c16dd65c6b2aceb6e356b45f5efe7cfaedc86ca3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antineoplastic Combined Chemotherapy Protocols - adverse effects</topic><topic>Humans</topic><topic>Lactate Dehydrogenases</topic><topic>Melanoma - drug therapy</topic><topic>Melanoma - genetics</topic><topic>Mutation</topic><topic>ORIGINAL REPORTS</topic><topic>Proto-Oncogene Proteins B-raf - genetics</topic><topic>Skin Neoplasms - drug therapy</topic><topic>Skin Neoplasms - genetics</topic><topic>Vemurafenib - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dummer, Reinhard</creatorcontrib><creatorcontrib>Flaherty, Keith T</creatorcontrib><creatorcontrib>Robert, Caroline</creatorcontrib><creatorcontrib>Arance, Ana</creatorcontrib><creatorcontrib>de Groot, Jan Willem B</creatorcontrib><creatorcontrib>Garbe, Claus</creatorcontrib><creatorcontrib>Gogas, Helen J</creatorcontrib><creatorcontrib>Gutzmer, Ralf</creatorcontrib><creatorcontrib>Krajsová, Ivana</creatorcontrib><creatorcontrib>Liszkay, Gabriella</creatorcontrib><creatorcontrib>Loquai, Carmen</creatorcontrib><creatorcontrib>Mandalà, Mario</creatorcontrib><creatorcontrib>Schadendorf, Dirk</creatorcontrib><creatorcontrib>Yamazaki, Naoya</creatorcontrib><creatorcontrib>di Pietro, Alessandra</creatorcontrib><creatorcontrib>Cantey-Kiser, Jean</creatorcontrib><creatorcontrib>Edwards, Michelle</creatorcontrib><creatorcontrib>Ascierto, Paolo A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dummer, Reinhard</au><au>Flaherty, Keith T</au><au>Robert, Caroline</au><au>Arance, Ana</au><au>de Groot, Jan Willem B</au><au>Garbe, Claus</au><au>Gogas, Helen J</au><au>Gutzmer, Ralf</au><au>Krajsová, Ivana</au><au>Liszkay, Gabriella</au><au>Loquai, Carmen</au><au>Mandalà, Mario</au><au>Schadendorf, Dirk</au><au>Yamazaki, Naoya</au><au>di Pietro, Alessandra</au><au>Cantey-Kiser, Jean</au><au>Edwards, Michelle</au><au>Ascierto, Paolo A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma</atitle><jtitle>Journal of clinical oncology</jtitle><addtitle>J Clin Oncol</addtitle><date>2022-12-20</date><risdate>2022</risdate><volume>40</volume><issue>36</issue><spage>4178</spage><epage>4188</epage><pages>4178-4188</pages><issn>0732-183X</issn><eissn>1527-7755</eissn><abstract>Combination treatment with BRAF and MEK inhibitors has demonstrated benefits on progression-free survival (PFS) and overall survival (OS) and is a standard of care for the treatment of advanced
V600-mutant melanoma. Here, we report the 5-year update from the COLUMBUS trial (ClinicalTrials.gov identifier: NCT01909453).
Patients with locally advanced unresectable or metastatic
V600-mutant melanoma, untreated or progressed after first-line immunotherapy, were randomly assigned 1:1:1 to encorafenib 450 mg once daily plus binimetinib 45 mg twice daily, vemurafenib 960 mg twice daily, or encorafenib 300 mg once daily. An updated analysis was conducted 65 months after the last patient was randomly assigned.
Five hundred seventy-seven patients were randomly assigned: 192 to encorafenib plus binimetinib, 191 to vemurafenib, and 194 to encorafenib. The 5-year PFS and OS rates with encorafenib plus binimetinib were 23% and 35% overall and 31% and 45% in those with normal lactate dehydrogenase levels, respectively. In comparison, the 5-year PFS and OS rates with vemurafenib were 10% and 21% overall and 12% and 28% in those with normal lactate dehydrogenase levels, respectively. The median duration of response with encorafenib plus binimetinib was 18.6 months, with disease control achieved in 92.2% of patients. In comparison, the median duration of response with vemurafenib was 12.3 months, with disease control achieved in 81.2% of patients. Long-term follow-up showed no new safety concerns, and results were consistent with the known tolerability profile of encorafenib plus binimetinib. Interactive visualization of the data presented in this article is available at COLUMBUS dashboard.
In this 5-year update of part 1 of the COLUMBUS trial, encorafenib plus binimetinib treatment demonstrated continued long-term benefits and a consistent safety profile in patients with
V600-mutant melanoma.</abstract><cop>United States</cop><pub>Wolters Kluwer Health</pub><pmid>35862871</pmid><doi>10.1200/JCO.21.02659</doi><tpages>11</tpages><orcidid>https://orcid.org/0000-0002-2279-6906</orcidid><orcidid>https://orcid.org/0000-0002-9493-0238</orcidid><orcidid>https://orcid.org/0000-0002-8322-475X</orcidid><orcidid>https://orcid.org/0000-0002-0451-2885</orcidid><orcidid>https://orcid.org/0000-0001-8846-8959</orcidid><orcidid>https://orcid.org/0000-0002-9638-0428</orcidid><orcidid>https://orcid.org/0000-0003-2896-1957</orcidid><orcidid>https://orcid.org/0000-0001-8530-780X</orcidid><orcidid>https://orcid.org/0000-0003-3524-7858</orcidid><orcidid>https://orcid.org/0000-0001-7921-2820</orcidid><orcidid>https://orcid.org/0000-0002-3402-0478</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0732-183X |
| ispartof | Journal of clinical oncology, 2022-12, Vol.40 (36), p.4178-4188 |
| issn | 0732-183X 1527-7755 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9916040 |
| source | MEDLINE; American Society of Clinical Oncology Online Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection |
| subjects | Antineoplastic Combined Chemotherapy Protocols - adverse effects Humans Lactate Dehydrogenases Melanoma - drug therapy Melanoma - genetics Mutation ORIGINAL REPORTS Proto-Oncogene Proteins B-raf - genetics Skin Neoplasms - drug therapy Skin Neoplasms - genetics Vemurafenib - therapeutic use |
| title | COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600-Mutant Melanoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T03%3A34%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=COLUMBUS%205-Year%20Update:%20A%20Randomized,%20Open-Label,%20Phase%20III%20Trial%20of%20Encorafenib%20Plus%20Binimetinib%20Versus%20Vemurafenib%20or%20Encorafenib%20in%20Patients%20With%20BRAF%20V600-Mutant%20Melanoma&rft.jtitle=Journal%20of%20clinical%20oncology&rft.au=Dummer,%20Reinhard&rft.date=2022-12-20&rft.volume=40&rft.issue=36&rft.spage=4178&rft.epage=4188&rft.pages=4178-4188&rft.issn=0732-183X&rft.eissn=1527-7755&rft_id=info:doi/10.1200/JCO.21.02659&rft_dat=%3Cproquest_pubme%3E2693779548%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2693779548&rft_id=info:pmid/35862871&rfr_iscdi=true |